{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:42:04Z","timestamp":1793479324381,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T00:00:00Z","timestamp":1297382400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2011.2","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T14:22:42Z","timestamp":1296829362000},"page":"e4-e4","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia"],"prefix":"10.1038","volume":"1","author":[{"given":"J","family":"Skavland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K M","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hadziavdic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Jonassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8","family":"Bruserud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B T","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,11]]},"reference":[{"key":"BFbcj20112_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"E Estey","year":"2006","unstructured":"Estey E, Dohner H . Acute myeloid leukaemia. Lancet 2006; 368: 1894\u20131907.","journal-title":"Lancet"},{"issue":"1","key":"BFbcj20112_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2008.1.1","volume":"2008","author":"B. Lowenberg","year":"2008","unstructured":"Lowenberg B . Acute myeloid leukemia: the challenge of capturing disease variety. Hematol Am Soc Hematol Educ Program 2008, 1\u201311.","journal-title":"Hematology"},{"key":"BFbcj20112_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/cncr.21589","volume":"104","author":"G Bug","year":"2005","unstructured":"Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104: 2717\u20132725.","journal-title":"Cancer"},{"key":"BFbcj20112_CR4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","volume":"104","author":"A Kuendgen","year":"2004","unstructured":"Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266\u20131269.","journal-title":"Blood"},{"key":"BFbcj20112_CR5","first-page":"986","volume":"90","author":"E Raffoux","year":"2005","unstructured":"Raffoux E, Chaibi P, Dombret H, Degos L . Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 986\u2013988.","journal-title":"Haematologica"},{"key":"BFbcj20112_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.leukres.2008.10.005","volume":"33","author":"A Ryningen","year":"2009","unstructured":"Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O . A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009; 33: 779\u2013787.","journal-title":"Leuk Res"},{"key":"BFbcj20112_CR7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.leukres.2008.12.014","volume":"33","author":"M Montillo","year":"2009","unstructured":"Montillo M, Ricci F, Tedeschi A, Cafro AM, Nosari AM, Nichelatti M et al. Twice daily fludarabine\/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. Leuk Res 2009; 33: 1072\u20131078.","journal-title":"Leuk Res"},{"key":"BFbcj20112_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1517\/13543784.17.11.1623","volume":"17","author":"A Ryningen","year":"2008","unstructured":"Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O . In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs 2008; 17: 1623\u20131633.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFbcj20112_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/leu.2008.354","volume":"23","author":"A Poggi","year":"2009","unstructured":"Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR . Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009; 23: 641\u2013648.","journal-title":"Leukemia"},{"key":"BFbcj20112_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/14728220902787628","volume":"18","author":"C Stapnes","year":"2009","unstructured":"Stapnes C, Gjertsen BT, Reikvam H, Bruserud O . Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs 2009; 18: 433\u2013455.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFbcj20112_CR11","first-page":"629","volume":"31","author":"F Bellos","year":"2008","unstructured":"Bellos F, Mahlknecht U . Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 2008; 31: 629\u2013633.","journal-title":"Onkologie"},{"key":"BFbcj20112_CR12","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969\u20136978.","journal-title":"EMBO J"},{"key":"BFbcj20112_CR13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/sj.leu.2403494","volume":"18","author":"PH Wiernik","year":"2004","unstructured":"Wiernik PH, Paietta E, Goloubeva O, Lee SJ, Makower D, Bennett JM et al. Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998). Leukemia 2004; 18: 1605\u20131610.","journal-title":"Leukemia"},{"key":"BFbcj20112_CR14","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1158\/1078-0432.CCR-05-1970","volume":"12","author":"N Anensen","year":"2006","unstructured":"Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT . A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 2006; 12: 3985\u20133992.","journal-title":"Clin Cancer Res"},{"key":"BFbcj20112_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2407-9-77","volume":"9","author":"AM Oyan","year":"2009","unstructured":"Oyan AM, Anensen N, Bo TH, Stordrange L, Jonassen I, Bruserud O et al. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 2009; 9: 77.","journal-title":"BMC Cancer"},{"key":"BFbcj20112_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/gm162","volume":"2","author":"SM Hjelle","year":"2010","unstructured":"Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjoholt G, Bruserud O et al. Clinical proteomics of myeloid leukemia. Genome Med 2010; 2: 41.","journal-title":"Genome Med"},{"key":"BFbcj20112_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/sj.bmt.1703346","volume":"29","author":"JF Abrahamsen","year":"2002","unstructured":"Abrahamsen JF, Bakken AM, Bruserud O, Gjertsen BT . Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases. Bone Marrow Transplant 2002; 29: 165\u2013171.","journal-title":"Bone Marrow Transplant"},{"key":"BFbcj20112_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nmeth872","volume":"3","author":"PO Krutzik","year":"2006","unstructured":"Krutzik PO, Nolan GP . Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006; 3: 361\u2013368.","journal-title":"Nat Methods"},{"key":"BFbcj20112_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2144\/03342mt01","volume":"34","author":"AI Saeed","year":"2003","unstructured":"Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374\u2013378.","journal-title":"Biotechniques"},{"key":"BFbcj20112_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood.V99.1.252","volume":"99","author":"M Benekli","year":"2002","unstructured":"Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 2002; 99: 252\u2013257.","journal-title":"Blood"},{"key":"BFbcj20112_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2353\/ajpath.2009.080537","volume":"174","author":"PB Gurpur","year":"2009","unstructured":"Gurpur PB, Liu J, Burkin DJ, Kaufman SJ . Valproic acid activates the PI3K\/Akt\/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. Am J Pathol 2009; 174: 999\u20131008.","journal-title":"Am J Pathol"},{"key":"BFbcj20112_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/0006-2952(92)90590-F","volume":"43","author":"S Ponchaut","year":"1992","unstructured":"Ponchaut S, van Hoof F, Veitch K . Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem Pharmacol 1992; 43: 644\u2013647.","journal-title":"Biochem Pharmacol"},{"key":"BFbcj20112_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1042\/bj3620755","volume":"362","author":"MF Silva","year":"2002","unstructured":"Silva MF, Ruiter JP, Overmars H, Bootsma AH, van Gennip AH, Jakobs C et al. Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 2002; 362: 755\u2013760.","journal-title":"Biochem J"},{"key":"BFbcj20112_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/toxsci\/kfi185","volume":"86","author":"V Tong","year":"2005","unstructured":"Tong V, Teng XW, Chang TK, Abbott FS . Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 2005; 86: 436\u2013443.","journal-title":"Toxicol Sci"},{"key":"BFbcj20112_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2004.06.028","volume":"118","author":"JM Irish","year":"2004","unstructured":"Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118: 217\u2013228.","journal-title":"Cell"},{"key":"BFbcj20112_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/blood-2004-03-1074","volume":"105","author":"A Glasow","year":"2005","unstructured":"Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A . Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005; 105: 341\u2013349.","journal-title":"Blood"},{"key":"BFbcj20112_CR27","first-page":"1925","volume":"10","author":"ZB Hu","year":"1996","unstructured":"Hu ZB, Minden MD, McCulloch EA . Regulation of the synthesis of bcl-2 protein by growth factors. Leukemia 1996; 10: 1925\u20131929.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bcj20112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bcj20112","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:38:10Z","timestamp":1672958290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj20112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,11]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,2]]}},"alternative-id":["BFbcj20112"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2011.2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,11]]},"assertion":[{"value":"3 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}